POHL BOSKAMP
SpecialtyPOHL BOSKAMP is a specialty pharmaceutical company focused on Cardiovascular, Immunology. Key products include GONITRO.
POHL BOSKAMP's Key Drugs
POHL BOSKAMP's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
POHL BOSKAMP's Recent FDA Approvals
New NDA/BLA approvals for POHL BOSKAMP over the last two years — novel drugs only, excluding generics and label supplements.
POHL BOSKAMP's Therapeutic Areas
POHL BOSKAMP's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Immunology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
POHL BOSKAMP's Top Competitors
POHL BOSKAMP's closest competitors by therapeutic-area and drug-target overlap include Novartis, Sanofi, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
POHL BOSKAMP Pipeline Snapshot
POHL BOSKAMP has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (1)
Company Info
- First Approval
- 1985-10-31
- Latest
- 2018-07-30
- Applications
- 3